Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma - PubMed (original) (raw)
Clinical Trial
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma
S Clive et al. Cancer Chemother Pharmacol. 1999.
Abstract
Background: Recurrent cutaneous breast cancer is difficult to manage, with surgery, radiotherapy and systemic therapy all having their limitations. Miltefosine is a topical cytostatic agent which may provide an alternative approach in its treatment.
Patients and methods: Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis. Miltefosine was applied topically to the skin at a dose of 2 drops/10 cm(2) skin area.
Results: Twenty-five patients were treated, most of whom had been heavily pre-treated. Treatment was continued for a median of 14 weeks (range 2-164). In 7 patients grade I skin toxicities were observed, and in 4 patients grade 3 local toxicities necessitated dose adjustments. A response was seen in 9 patients (1 complete response, 2 partial responses, 6 minor responses) giving a total response rate of 36%, with stable disease in 11 patients (44%) and progressive disease in 5 (20%). Those lesions which were superficial or < 2 cm in diameter were most likely to respond.
Conclusions: Miltefosine, either used alone or in conjunction with other therapies for distant metastases, is an effective and tolerable local treatment for cutaneous breast cancer.
Similar articles
- Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Leonard R, Hardy J, van Tienhoven G, Houston S, Simmonds P, David M, Mansi J. Leonard R, et al. J Clin Oncol. 2001 Nov 1;19(21):4150-9. doi: 10.1200/JCO.2001.19.21.4150. J Clin Oncol. 2001. PMID: 11689583 Clinical Trial. - Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Smorenburg CH, Seynaeve C, Bontenbal M, Planting AS, Sindermann H, Verweij J. Smorenburg CH, et al. Anticancer Drugs. 2000 Nov;11(10):825-8. doi: 10.1097/00001813-200011000-00006. Anticancer Drugs. 2000. PMID: 11142690 Clinical Trial. - Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Terwogt JM, Mandjes IA, Sindermann H, Beijnen JH, ten Bokkel Huinink WW. Terwogt JM, et al. Br J Cancer. 1999 Mar;79(7-8):1158-61. doi: 10.1038/sj.bjc.6690184. Br J Cancer. 1999. PMID: 10098751 Free PMC article. Clinical Trial. - Topical agents and dressings for fungating wounds.
Adderley U, Smith R. Adderley U, et al. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003948. doi: 10.1002/14651858.CD003948.pub2. Cochrane Database Syst Rev. 2007. PMID: 17443534 Updated. Review. - Miltefosine and cutaneous leishmaniasis.
Machado PR, Penna G. Machado PR, et al. Curr Opin Infect Dis. 2012 Apr;25(2):141-4. doi: 10.1097/QCO.0b013e3283509cac. Curr Opin Infect Dis. 2012. PMID: 22248979 Review.
Cited by
- Current Advances in the Biomedical Applications of Quantum Dots: Promises and Challenges.
Le N, Kim K. Le N, et al. Int J Mol Sci. 2023 Aug 11;24(16):12682. doi: 10.3390/ijms241612682. Int J Mol Sci. 2023. PMID: 37628860 Free PMC article. Review. - A Novel Protocol for the Synthesis of 1,2,4-Oxadiazoles Active against Trypanosomatids and Drug-Resistant Leukemia Cell Lines.
Pitasse-Santos P, Salustiano E, Pena RB, Chaves OA, da Fonseca LM, da Costa KM, Santos CADN, Reis JSD, da Costa Santos MAR, Previato JO, Previato LM, Freire-de-Lima L, Romeiro NC, Pinto-da-Silva LH, Freire-de-Lima CG, Decotè-Ricardo D, Freire-de-Lima ME. Pitasse-Santos P, et al. Trop Med Infect Dis. 2022 Nov 28;7(12):403. doi: 10.3390/tropicalmed7120403. Trop Med Infect Dis. 2022. PMID: 36548658 Free PMC article. - Quinazolinone-based hybrids with diverse biological activities: A mini-review.
Rezaeinasab R, Jafari E, Khodarahmi G. Rezaeinasab R, et al. J Res Med Sci. 2022 Sep 27;27:68. doi: 10.4103/jrms.jrms_1025_21. eCollection 2022. J Res Med Sci. 2022. PMID: 36353342 Free PMC article. Review. - Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.
Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, Llurba E, Rovira R, Ruiz R, Martín-Lorente C, Corchero JL, Céspedes MV. Rodríguez F, et al. Biomolecules. 2022 Jun 4;12(6):784. doi: 10.3390/biom12060784. Biomolecules. 2022. PMID: 35740909 Free PMC article. Review. - Cutaneous metastasectomy: Is there a role in breast cancer? A systematic review and overview of current treatment modalities.
Huang S, Parekh V, Waisman J, Jones V, Yuan Y, Vora N, Li R, Jung J, Kruper L, Abdulla F, Fong Y, Li WY. Huang S, et al. J Surg Oncol. 2022 Aug;126(2):217-238. doi: 10.1002/jso.26870. Epub 2022 Apr 7. J Surg Oncol. 2022. PMID: 35389520 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical